

RD General Agenda Topics – October 20, 2020

New Active Ingredients (include original PRIA date)

- Inpyrfluxam – Complete
- Pethoxamid – complete
- Pyridate – complete
- Tiafenacil – complete
- Tetraniliprole – PD signed. PRIA date 12/24/20 (Original PRIA date 3/27/19) (IVB3)
- **Broflanilide – PD to the RD-IO this week.** PRIA date negotiated to 11/30/20 (Original PRIA date 12/19/19) (IVB1)
- **Fluindapyr – PD to the RD-IO this week. Team spoke to company – restricting applications in almonds to post-bloom.** PRIA Date 11/16/20 (Original PRIA date 5/29/20) (FB)
- **Trifludimoxazin** – Team is resolving OGC comments. (get update from Rachel)

Chemical Actions

- Dicamba (Dan K)
 - **Docs due to Alex Wednesday and Thursday**
- Antibiotics – developing comparison schedule (Cynthia)
 - Streptomycin – developing RTC
 - Oxytet – cherry; Dec; public process
 - Consultation with partners – Kasugamycin (almond, peach, apricot)
 - **OD briefing in November**
- Aldicarb – registrant agreed to 60 days; water refinement; RD is regrouping with EFED/HED; Another renegotiation likely (Marion)
- **Spirodiclofen – Gowan purchasing reg review vs. new AI (Meredith)**
- Cyclaniliprole/flonicamid – RD IO review; first residential use; public process; bee language; coming to OPP IO soon
- **Seresto – pet collar with high rate of incidents (death and neuro); does OPP-IO want a briefing?**
Other Actions - AA-Level/OD/High Visibility Items
- COVID-19 Activities – Sect 18s –
 - **SW2 – OK has submitted**

Ex. 5 Deliberative Process (DP)

- Formulator's exemption (Bo)
 - **Drafting new memo (awaiting comments from OGC)**
 - Syngenta – request to cancel Atticus registrations
 - OGC is proposing that we write up something short that explains that, during the time of approval, RD was following all of our current policies.

- OECA suggested a **Ex. 5 Deliberative Process (DP)**

Ex. 5 Deliberative Process (DP)

- **Spartan Mosquito – updating one pager**
- PFAS – follow-ups with R1 – any updates from your level?
- AAPCO Label Project – VA, IN, ME etc. plus EPA
- RD A3 FR streamline – on track with avg cost \$1,914 (target \$1,980); internal template in development (Catherine/Nancy)
- Gold Seals –OMB covid flash review; website comms expected following OMB review; will provide webinar to CLA/RISE workgroup in mid-November– (Marion)

Speaking Engagements –

- Gold Seal Updates for CLA/RISE Workgroup (Catherine Aubee, Shanta Adeeb, Marion Johnsons, ITRMD participant), mid-Nov (date TBD)

P

Ex. 5 Deliberative Process (DP)